SAN DIEGO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a...
– No differentiation syndrome events reported – – 100% CR rate with 7+3 in newly diagnosed NPM1-m and KMT2A-r...
– Funding from existing investors, including EcoR1 Capital, an affiliate of Deerfield Management and Suvretta...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.